Researchers at the University of Illinois at Chicago College of Medicine have been awarded more than $11.7 million to study the pathology of severe lung injury.
The study, part of a multi-pronged investigation into acute lung injury, or ALI, is funded by the National Heart, Lung and Blood Institute, one of the National Institutes of Health.
ALI and its even more severe form, acute respiratory distress syndrome, result from pulmonary edema -- leaky blood vessels -- and inflammation. Direct lung injury from infection or indirect injury from trauma, sepsis, pancreatitis, transfusions, radiation or drug overdose can trigger ALI. It is fatal almost 40 percent of the time.
"We are now ready to address the very important, clinically relevant aspects of the pathobiology of ALI and investigate novel therapeutic approaches," said Natarajan, program director and professor of pharmacology and medicine at UIC, who has been studying ALI for 20 years. Natarajan also co-directs the Institute for Personalized Respiratory Medicine at UIC with Dr. Joe G.N. "Skip" Garcia, University of Illinois vice president for health affairs, UIC vice chancellor for research and Earl M. Bane Professor of Medicine.
The NIH Program Project Grant is an interdisciplinary investigation of a bio-active lipid called sphingosine-1-phosophate, or S1P, and its receptors and their role in lung cell signaling, inflammation and injury caused by sepsis or radiation.
One project, led by Natarajan, will use animal and cell-culture models to investigate how S1P is generated inside cells and how it exerts a protective effect in ALI -- an effect which Garcia, Natarajan and their collaborators had demonstrated previously in animal models of ALI.
A second project, headed by Garcia, will investigate the role of S1P receptors in ALI.
"Dr. Garcia brings cutting-edge expertise in genomics, genetics and clinical medicine to the project," Natarajan said, "a
|Contact: Jeanne Galatzer-Levy|
University of Illinois at Chicago